Thomas Barfod - Coloplast A/S Director, Employee Representative
| CLPBF Stock | USD 121.15 0.15 0.12% |
Director
Mr. Thomas Barfod has served as Employee Representative on the Board of Directors at Coloplast AS since December 2006. He was employed by the Company since 1992. He has commercial training and basic vocational education. He is Senior Controller. since 2006.
| Age | 53 |
| Tenure | 18 years |
| Phone | 45 49 11 11 11 |
| Web | https://www.coloplast.com |
Coloplast A/S Management Efficiency
The company has return on total asset (ROA) of 0.1714 % which means that it generated a profit of $0.1714 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7507 %, meaning that it generated $0.7507 on every $100 dollars invested by stockholders. Coloplast A/S's management efficiency ratios could be used to measure how well Coloplast A/S manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Claire Pomeroy | Becton Dickinson and | 65 | |
| Marshall Larsen | Becton Dickinson and | 72 | |
| Christopher Jones | Becton Dickinson and | 65 | |
| Claire Fraser | Becton Dickinson and | 65 | |
| Rebecca Rimel | Becton Dickinson and | 69 | |
| Timothy Ring | Becton Dickinson and | 63 | |
| David Melcher | Becton Dickinson and | 66 | |
| Paul Saillant | EssilorLuxottica Socit anonyme | 64 | |
| Paul Saillant | Essilor International SA | 64 | |
| Sebastian Frericks | Carl Zeiss Meditec | N/A | |
| Bertram Scott | Becton Dickinson and | 69 | |
| Jeffrey Henderson | Becton Dickinson and | 56 | |
| Francesco Milleri | EssilorLuxottica Socit anonyme | 64 | |
| Catherine Burzik | Becton Dickinson and | 70 | |
| Kaoru Asano | Sysmex Corp | 65 | |
| Sebastian Frericks | Carl Zeiss Meditec | N/A | |
Management Performance
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 |
Coloplast A/S Leadership Team
Elected by the shareholders, the Coloplast A/S's board of directors comprises two types of representatives: Coloplast A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coloplast. The board's role is to monitor Coloplast A/S's management team and ensure that shareholders' interests are well served. Coloplast A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coloplast A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ellen Bjurgert, VP Relations | ||
| Allan Rasmussen, Executive VP of Global Operations | ||
| Alain Morvan, Senior Vice President Sales Europe | ||
| Thomas Barfod, Director, Employee Representative | ||
| Nicolai Andersen, Senior Vice President Wound Care | ||
| Anders LonningSkovgaard, CFO, Executive Vice President Member of the Executive Management | ||
| Kristian Villumsen, Executive VP of Chronic Care | ||
| Paul Marcun, Senior Vice President Emerging Markets | ||
| Dorthe Ronnau, VP Culture | ||
| Dennis Kaysen, Director Communications |
Coloplast Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Coloplast A/S a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.75 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.30 % | |||
| Current Valuation | 28.84 B | |||
| Shares Outstanding | 194.31 M | |||
| Shares Owned By Insiders | 35.00 % | |||
| Shares Owned By Institutions | 25.53 % | |||
| Price To Earning | 37.47 X | |||
| Price To Book | 22.60 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Coloplast Pink Sheet
Coloplast A/S financial ratios help investors to determine whether Coloplast Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Coloplast with respect to the benefits of owning Coloplast A/S security.